CELC
Celcuity Inc.
$113.51
+4.61
(+4.23%)
Mkt Cap
5.53B
Volume
973,358
52W Range
13.35-151.02
Sector
Healthcare
Beta
0.16
EPS (TTM)
-3.89
P/E Ratio
-26.39
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (177.04M) | (111.78M) | (63.78M) | (40.37M) | (29.61M) | (9.47M) | (7.36M) | (7.48M) | (6.25M) | (3.31M) | (2.26M) |
| EPS | -3.78 | -2.83 | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Free Cash Flow | (153.53M) | (83.72M) | (53.91M) | (36.17M) | (20.39M) | (7.24M) | (6.38M) | (6.71M) | (5.19M) | (2.93M) | (2.06M) |
| FCF / Share | -2.92 | -2.12 | -2.28 | -2.35 | -1.52 | -0.70 | -0.62 | -0.66 | -0.70 | -0.44 | -0.33 |
| Operating CF | (153.28M) | (83.47M) | (53.81M) | (36.01M) | (20.31M) | (7.15M) | (6.00M) | (6.08M) | (4.95M) | (2.89M) | (1.98M) |
| Total Assets | 466.56M | 245.12M | 191.22M | 175.70M | 85.91M | 12.96M | 20.28M | 26.03M | 31.97M | 6.06M | 5.30M |
| Total Debt | 195.38M | 97.95M | 37.45M | 35.24M | 14.89M | 262,488 | 256,137 | 25,608 | 0 | 0 | 0 |
| Cash & Equiv | 165.70M | 22.51M | 30.66M | 24.57M | 84.29M | 11.64M | 18.74M | 15.94M | 2.64M | 5.86M | 5.07M |
| Book Value | 100.56M | 115.62M | 139.77M | 133.77M | 68.71M | 11.70M | 19.30M | 25.35M | 31.39M | 5.61M | 5.02M |
| Return on Equity | -1.76 | -0.97 | -0.46 | -0.30 | -0.43 | -0.81 | -0.38 | -0.30 | -0.20 | -0.59 | -0.45 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.84M) | (50.97M) | (43.80M) | (45.27M) | (37.00M) | (36.65M) | (29.79M) | (23.72M) | (21.61M) | (18.85M) | (18.40M) | (14.59M) |
| EPS | -0.97 | -0.96 | -0.92 | -1.04 | -0.86 | -0.85 | -0.70 | -0.62 | -0.64 | -0.65 | -0.83 | -0.66 |
| Free Cash Flow | (55.31M) | (36.45M) | (44.91M) | (36.25M) | (35.91M) | (27.82M) | (20.61M) | (18.13M) | (17.16M) | (18.57M) | (12.80M) | (9.67M) |
| FCF / Share | -1.02 | -0.69 | -1.00 | -0.83 | -0.83 | -0.65 | -0.48 | -0.47 | -0.51 | -0.64 | -0.58 | -0.44 |
| Operating CF | (55.06M) | (36.40M) | (44.82M) | (36.21M) | (35.85M) | (27.77M) | (20.56M) | (18.07M) | (17.07M) | (18.54M) | (12.75M) | (9.66M) |
| Total Assets | 410.16M | 466.56M | 476.00M | 183.59M | 218.13M | 245.12M | 273.04M | 292.54M | 188.18M | 191.22M | 142.38M | 153.52M |
| Total Debt | 195.58M | 195.38M | 320.35M | 99.42M | 98.71M | 97.95M | 97.19M | 96.51M | 37.93M | 37.45M | 36.97M | 36.49M |
| Cash & Equiv | 145.19M | 165.70M | 74.25M | 46.35M | 16.48M | 22.51M | 12.60M | 30.46M | 31.21M | 30.66M | 25.76M | 32.24M |
| Book Value | 53.52M | 100.56M | 116.96M | 44.38M | 86.67M | 115.62M | 149.71M | 176.68M | 133.74M | 139.77M | 92.90M | 110.13M |
| Return on Equity | -0.99 | -0.51 | -0.37 | -1.02 | -0.43 | -0.32 | -0.20 | -0.13 | -0.16 | -0.13 | -0.20 | -0.13 |
CELC News
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
What's Going On With Celcuity Stock On Tuesday?
Celcuity plunges after experimental breast cancer treatment data disappoints
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer